Defining the dose range for esmolol used in electroconvulsive therapy hemodynamic attenuation

Area of Science:

• Anesthesiology
• Cardiology
• Pharmacology

Background:

• Electroconvulsive therapy (ECT) can induce significant sympathetic stimulation, leading to tachycardia and hypertension.
• Managing these cardiovascular responses is crucial for patient safety during ECT.

Purpose of the Study:

• To evaluate the clinical effectiveness of esmolol in controlling sinus tachycardia and arterial blood pressure increases during ECT.
• To determine the optimal dosage of esmolol for managing ECT-induced cardiovascular changes.

Main Methods:

• A double-blind, randomized Latin-Square study was conducted with 20 patients (ASA physical status I-III).
• Patients received placebo or varying doses of esmolol (500 mcg/kg bolus followed by low, medium, or high dose infusion) during ECT.
• Heart rate and blood pressure were monitored before, during, and after the ECT procedure.

Main Results:

• Esmolol significantly decreased mean heart rate from minutes 3 to 7 post-stimulus compared to placebo.
• Maximum heart rate after seizure was significantly lower in esmolol groups (112-124 bpm) versus placebo (147 bpm).
• Esmolol demonstrated dose-dependent control of ECT-induced tachycardia.

Conclusions:

• Esmolol is effective in mitigating the cardiovascular stress response to ECT.
• The use of esmolol can improve patient outcomes and safety during electroconvulsive therapy.
• Further research may explore optimal infusion rates for different patient populations.